Campbell University

CU FIND
Osteopathic Medicine, Jerry M. Wallace School
of

Faculty Research and Publications

2009

Antibacterial efficacy of core-shell nanostructures encapsulating
gentamicin against an in vivo intracellular Salmonella model
A. Ranjan
N. Pothayee
M. N. Seleem
R. D. Tyler
B. Brenseke
See next page for additional authors

Follow this and additional works at: https://cufind.campbell.edu/medicine_school
Part of the Medicine and Health Sciences Commons

Authors
A. Ranjan, N. Pothayee, M. N. Seleem, R. D. Tyler, B. Brenseke, N. Sriranganathan, J. S. Riffle, and R.
Kasimanickam

International Journal of Nanomedicine

Dovepress
open access to scientific and medical research

o R i g inal r e s e ar c h

Open Access Full Text Article

Antibacterial efficacy of core-shell nanostructures
encapsulating gentamicin against an in vivo
intracellular Salmonella model
This article was published in the following Dove Press journal:
International Journal of Nanomedicine
1 December 2009
Number of times this article has been viewed

Ashish Ranjan 1
Nikorn Pothayee 2,3
Mohammed N Seleem 2
Ronald D Tyler Jr 4
Bonnie Brenseke 4
Nammalwar Sriranganathan2,4
Judy S Riffle 2,3
Ramanathan Kasimanickam 1
Department of Large Animal Clinical
Sciences, 2Institute for Critical
Technology and Applied Science,
3
Macromolecules and Interfaces
Institute, 4Department of Biomedical
Sciences and Pathobiology, Virginia
Polytechnic Institute and State
University, Blacksburg, VA
1

Correspondence: Nammalwar
Sriranganathan
Department of Biomedical Sciences and
Pathobiology, Virginia Polytechnic Institute
and State University Blacksburg VA, USA
Tel +1 540 231 7171
Email nathans@vt.edu

submit your manuscript | www.dovepress.com

Dovepress

Abstract: Pluronic based core-shell nanostructures encapsulating gentamicin were designed
in this study. Block copolymers of (PAA–+Na-b-(PEO-b-PPO-b-PEO)-b-PAA–  +Na) were
blended with PAA– Na+ and complexed with the polycationic antibiotic gentamicin to form
nanostructures. Synthesized nanostructures had a hydrodynamic diameter of 210 nm, zeta
potentials of –0.7 (±0.2), and incorporated ∼20% by weight of gentamicin. Nanostructures upon
co-incubation with J774A.1 macrophage cells showed no adverse toxicity in vitro. Nanostructures
administered in vivo either at multiple dosage of 5 µg g–1 or single dosage of 15 µg g–1 in AJ-646
mice infected with Salmonella resulted in significant reduction of viable bacteria in the liver
and spleen. Histopathological evaluation for concentration-dependent toxicity at a dosage of
15 µg g–1 revealed mineralized deposits in 50% kidney tissues of free gentamicin-treated mice
which in contrast was absent in nanostructure-treated mice. Thus, encapsulation of gentamicin
in nanostructures may reduce toxicity and improve in vivo bacterial clearance.
Keywords: gentamicin, core-shell nanostructures, Salmonella

Introduction
Delivery systems capable of transferring cell-impermeable drugs into cells have
tremendous potential for improving therapeutic efficacies in vivo.1 In the last few
decades, nanotechnology has been increasingly employed in new drug delivery systems
(DDS). DDS developed through nanotechnology may allow for reductions in dosage
and dosage frequency and may also prevent toxicity associated with conventional
therapy. This may be especially beneficial for chronic intracellular infections which
now require long-duration combination therapies.2 For example, aminoglycosides are
a common class of antibiotics utilized clinically for treating bacterial infections. They
have broad activities against both Gram-negative and Gram-positive bacteria.3 However,
the action of aminoglycosides is concentration-dependent and free gentamicin filters
rapidly through the renal system, thus necessitating high dosages. Administration of
high dosages of aminoglycosides may result in nephrotoxicity and ototoxicity, which
may be prevented with nanomedicine-based therapy.4
To achieve intracellular delivery of aminoglycosides, several drug delivery
strategies have been utilized including liposomes and polymeric carriers.5,6 These drug
delivery systems have improved the intracellular delivery of aminoglycosides, but
suffer from low drug incorporation. Core-shell drug delivery systems have recently
attracted considerable attention due to their unique ability in encapsulating charged
therapeutic molecules.2 The unique ability is conferred to the core-shell structures

International Journal of Nanomedicine 2009:4 289–297
© 2009 Ranjan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article
which permits unrestricted noncommercial use, provided the original work is properly cited.

289

Dovepress

Ranjan et al

mainly by fabricating the core to contain high amounts of
ionic species and tailoring shell with specific hydrophobic/
hydrophilic chemistry as shown schematically in Figure 1.
This may result in encapsulation of high payload of oppositely
charged ionic species like gentamicin inside the cores and
successful interaction of the shell’s hydrophobic segment
with the cell membranes.
We previously reported synthesis of core-shell nanostructure with amphiphilic shell containing pluronic F68 which
can incorporate up to ∼25% by weight of gentamicin and their
in vitro trafficking and efficacy in infected macrophage cells.22
Pluronics have widely been used as excipients in pharmaceutics.7 Pluronic triblock copolymers are comprised of
hydrophilic poly(ethylene oxide) (PEO) terminal blocks with
a hydrophobic poly(propylene oxide) (PPO) central block
(ie, PEO-b-PPO-b-PEO) in a basic A-B-A structure: EOx/2POy-EOx/2.8 Different pluronic copolymers are characterized
distinctly by their hydrophilic-lipophilic balance (HLB).
For example, the HLB of pluronic F68 is 29 whereas that
of pluronic P85 is 16. Therefore, pluronic F68 is relatively
less hydrophobic than pluronic P85. Pluronics have been
investigated extensively for cancer chemotherapy of multidrug resistant (MDR) tumors.9 By varying the lengths of the

Anionic block copolymers

hydrophobic propylene oxide (y) and hydrophilic ethylene
oxide (x) segments, increased potency and intracellular
uptake of the DDS were seen in the tumor cells.10 Studies on
KBv cell lines have shown that the accumulation of pluronics
inside the cells is dependent on HLB. In general, pluronics
with HLB of 20–29 had minimal effect on drug transport.
In contrast, pluronics with HLB less than 20 exhibited
varying degree of activity against MDR cells.8 Thus, the
triblock arrangement provides an advantage of altering
the hydrophilic/hydrophobic balance to suit a particular
therapeutic application.11 Therefore, its incorporation in DDS
for cell specific therapy may be highly favorable,12 especially
for intracellular infections.
Preclinical studies conducted previously with biodegradable
DDS made from a combination of poly(ε-caprolactone) (PCL)
and Pluronic F68 did not cause any adverse toxicological
response in rats or dogs.18 In this study, we designed coreshell nanostructure by synthesizing PAA– +Na-b-PEO-b-PPOb-PEO-b-PAA– +Na block copolymers and complexed them
with gentamicin to form nanostructures with PEO-b-PPO-bPEO shells, and PAA cores containing the antibiotic shown
schematically in Figure 1. The efficacies of these core-shell
nanostructures were investigated in an in vivo intracellular

Aminoglycosides

Inonic condensation

Hydrophobic segment

Hydrophilic segment

Amphiphilic core-shell complexes
Figure 1 Schematic illustration of methodology for preparing core-shell nanostructure encapsulating gentamicin.
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Salmonella mouse infection model. Our objectives also
included an evaluation of the observed reduction in gentamicin toxicity that resulted from encapsulation in the cores.

the core-shell nanostructure and D2G for mice group treated
with free gentamicin alone).

Materials and methods
Materials

The solute sizes and zeta potentials of the complexes were
characterized by DLS with a Zetasizer 1000 HS with laser
diffractometry (Malvern Instruments, Malvern, UK) at a
scattering angle of 90o. Each complex (1 mg) was dispersed
in 1 mL of DI water and analyzed. Measurements were done
in triplicate for each batch of particles. The results were taken
as the average of three measurements.

All chemicals were purchased from Sigma-Aldrich unless
otherwise noted. t-Butyl acrylate (tBA) was distilled from
calcium hydride under vacuum prior to polymerization.
Pluronic F68 (Mn ∼8,300 g mol–1) was kindly provided by
BASF (NJ, USA). Pluronic F68 and polyethylene oxide
monomethyl ether (Mn ∼2,000 g mol–1) were dried under
vacuum at 70°C for 48 hours prior to any polymerizations.

Preparation of core-shell nanostructures
loaded with gentamicin
Block copolymers of poly(sodium acrylate)-(PEO-b-PPOb-PEO)-poly(sodium acrylate) (PAA– +Na-(PEO-b-PPOb-PEO)-PAA – +Na) and PEO-PAA - +Na were prepared
according to a previously published procedure.13 Briefly,
PEO-b-PPO-b-PEO (Pluronic F68) with hydroxyl terminal
groups was derivatized with 2-bromoisobutyryl bromide
to provide bromoalkyl functional endgroups and then
t-butyl acrylate was polymerized by controlled atom transfer radical polymerization (ATRP). The protective t-butyl
groups were subsequently removed with trifluoroacetic acid
and the polymer was neutralized with NaOH to form the
sodium salt (PAA- +Na-(PEO-b-PPO-b-PEO)-PAA- +Na). In
a 100-mL round-bottom flask, 34 mg of PAA- +Na-(PEOb-PPO-b-PEO)-PAA- +Na (1.90 × 10-4 eq of anions) and
16 mg of PAA- +Na (1.6 × 10–4 eq of anions) were dissolved
in 50 mL of DI water and the pH was adjusted to 7 with
NaOH (1 N). The solution was placed in a sonication bath
and 5 mL of gentamicin sulfate solution (10 mg mL-1 gentamicin sulfate, equal to 30 mg gentamicin, 3.5 × 10-4 eq of
cations) was added via syringe to form a turbid dispersion.
Any non-complexed free gentamicin sulfate was removed
by dialysis against 4 L of deionized (DI) water at 4°C for
24 hours and the core-shell nanostructures were recovered
by freeze-drying. Core-shell nanostructure prepared by this
methodology was later utilized for in vivo treatment efficacy
studies at dosage of 5 µg g–1 and 15 µg g–1 respectively. The
nomenclature describing the mice treated at 5 µg g–1 adopted
for this paper is D1 (D1N for the group treated with coreshell nanostructure and D1G for the group treated with free
gentamicin alone). Similarly, the mice administered with
15 µg are designated as D2 (D2N for the group treated with

International Journal of Nanomedicine 2009:4

Characterization of complexes

Gentamicin concentration
in the nanostructure
The amount of gentamicin loaded into the core-shell
nanostructures was determined via an o-phthalaldehyde
assay according to a previously published procedure. 14
To quantify the amount of encapsulated gentamicin, the
complexes were dissolved in borate buffer at pH 9.7 to
disintegrate the particles and release the drug in the free
amine form. The primary amine on gentamicin was then
reacted with an excess of phthalaldehyde in the presence of
mercaptoethanol to produce a derivative that was quantified
via UV-visible spectroscopy. For derivatization, gentamicin
solution, phthalaldehyde reagent containing mercaptoethanol,
and isopropanol (to avoid precipitation of the products)
were reacted for 30 minutes at room temperature, and the
absorbance of the product was measured at 335 nm.

In vitro MTS toxicity assessment
An in vitro homogeneous, colorimetric CellTiter 96®
AQueous Non-Radioactive Cell Proliferation MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) Assay (Promega Corporation)
for determining the numbers of viable J774A.1 cells was
utilized to determine any cytotoxicity of the polymers and
the nanostructures. Briefly, ∼2 × 104 J774A.1 cells suspended
in 200 µL of DMEM supplemented with 10% fetal bovine
serum (FBS), L-glutamine, NaHCO3, pyridoxine-HCl, and
4.5% glucose and preserved with 1% penicillin-streptomycin
solution were seeded in 96-well plates and incubated for
24 hours at 37°C in a 5% CO2 atmosphere. The J774A.1 cells
were further incubated with 250 µg/mL of free gentamicin,
copolymer, core-shell nanostructures encapsulating
gentamicin along with the appropriate untreated control
for 24 hours. The culture media was discarded, and the
cells in each well were washed with PBS and re-suspended
with 100 µL of cell culture media. Then 20 µL of CellTiter
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96® AQueous reagent solution was pipetted into each well,
and the plates were incubated for 4 hours at 37°C in a humidified 5% CO2 atmosphere. The absorbance at 490 nm was
recorded using a 96-well Elisa plate reader (SoftMax Pro
Inc., USA). Results were expressed as the percentage mean
absorbance by cells upon incubation with various treatments
(nanostructure, copolymer or free gentamicin) with respect
to incubation in untreated control.

In vivo toxicity
To assess concentration/dose dependent toxicity, kidney
tissue from the untreated, D2N- or D2G-treated mice were
harvested and assessed for histopathological changes.
The kidneys were fixed in 10% neutral buffered formalin,
routinely processed into paraffin blocks, and 5 micron
sections were stained with hematoxylin and eosin on glass
slides (Virginia-Maryland Regional College of Veterinary
Medicine, Veterinary Teaching Hospital). Tissue samples
were examined independently by light microscopy and
scored by two veterinary pathologists. The pathologists were
blinded to obtain unbiased assessment. The kidneys were
scored on a scale of 0 to 4 based on the degree of inflammation as reported before.15,16 Briefly, a semi-quantitative scale
of change consisting of whole numbers with scores from
0 to 4 was given as (0) = unremarkable, (1) = minimum,
(2) = mild, (3) = moderate, and (4) = marked. Changes include
inflammation (infiltration of inflammatory cells), necrosis
(morphologic changes of renal parenchyma cells consistent
with degeneration and necrosis) and vascular disruptions
(hemorrhage, edema and other signs of vascular leakage).
The percentage of affected section of tissue being affected is
what was used to score any change viz. 0% = unremarkable
(0), 0% to 5% = minimal (1), 6% to 10% = mild (2), 11%
to 20% = moderate (3), 20% = marked.4 Furthermore, any
samples with the presence of mineral deposits associated
with regions of inflammation were assigned an additional
0.5 points to take mineralization into account for final
analysis.

Treatment efficacy of core-shell
nanostructures against against
S. typhimurium
S. enterica typhimurium (wild type) was grown overnight
in Luria-Bertani (LB) broth, centrifuged, washed in PBS
and serially diluted to achieve a final suspension containing
10,000 colony forming units (cfu) per mL. Twenty-five AJ
646 mice (6 to 8 weeks old) were injected intraperitoneally
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(ip) with 100 µL of inocula containing 1000 cfu per mouse.
After 48 hours of infection, 5 AJ 646 mice per group were
treated with either D1G (in PBS) or the D1N ip at a recommended dosage of 5 µg g–1 of body weight.17 The dosage
was repeated twice at intervals of 24 hours, ip for a total
of 3 doses. At day 2 (post third ip injection), the mice were
euthanized, the spleens and livers were removed aseptically,
and the organs were crushed and homogenized for 1 to 2 min
in the presence of 2 mL of LB broth. Aliquots (500 µL)
of the organ suspensions were serially diluted in 4.5 mL of
LB broth to a maximum of 105-fold dilution. Subsequently,
the dilutions were plated on tryptic soy agar plates, incubated
overnight at 37°C, and the resulting grey mucoid, discrete
colonies were counted for plates containing between 30 and
300 colonies. Also, two groups of Salmonella-infected mice
(5 mice per group) were administered with either D2G or
the D2N at a single ip dosage of 15 µg g–1 of body weight
to determine any concentration-dependent toxicity on the
kidneys. The mice were euthanized at day 5 of the study
along with the normally administered dosed mice.

Statistical analysis
The mean absorbance in the MTS assay was compared
between the groups using analysis of variance. The kidney
scores were compared between the three groups using the
Kruskal-Wallis Test followed by Dunn’s procedure for
multiple comparisons. Statistical significance was set to
alpha = 0.05. Analyses were performed using JMP (ANOVA
and Kruskal-Wallis test) and SAS (Dunn’s procedure for
multiple comparisons).

Results
Core-shell nanostructures
DLS showed that polymer-gentamicin core-shell
nanostructures had a mean intensity average diameter of
210 (±17) nm and had negligible zeta potentials, ranging
from –0.7 (±0.2) mv. The amount of gentamicin encapsulation based on a UV spectroscopic analyis of an o-phthalaldehyde-mercaptoethanol derivative of the drug showed an
encapsulation of ∼25%. The rather high drug concentration
of ∼25% by weight is attributed to strong interactions between
the cationic gentamicin and the anionic polymer.

In vitro MTS assay
MTS assays conducted on the free gentamicin, copolymer,
core-shell nanostructure and untreated control showed
no significant differences in percentage mean absorption
between various treatments (Figure 2), indicating that the
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In vitro cytotoxicity assay

% Cell viability

100

75

50

25

0
Control

Free gentamicin

Polymer alone

Core-shell
nanostructures

Treatment
Figure 2 MTS assay showing the percentage mean absorbance (depicted by % cell viability at wavelength of 490 nm) after incubating J774A.1 cells with 250 µg mL–1 of core-shell
nanostructures along with appropriate controls. Results are expressed as means ± SD of 6 measurements. **P  0.05, ANOVA.
Notes: No significant difference between treatments at P  0.05.

polymers at doses similar to that of the free gentamicin or
untreated control were non-toxic in vitro.

In vivo toxicity assessment
Based on degrees of inflammation and mineralization of
kidney tissues, D2N had a median score of 0 (range 0 to
0.50), untreated control 0 (range 0 to 0.75) and D2G 0.75
(range 0 to 2.50), determined by compiling the individual

data scored by the pathologists (Table 1). The Kruskal-Wallis
statistical test showed that various treatments had a statistically
significant effect on kidney scores (P = 0.0288). Moreover,
Dunn’s procedure for multiple comparisons showed that the
median kidney score for D2G was significantly greater than
the median kidney score for D2N (P = 0.0223). The other
two comparisons (D2G vs the untreated control, and the
untreated control vs D2N) did not differ significantly.

Table 1 Kidney scoring by individual pathologist
Kidney no.

Kidney score – D2N

Kidney score – untreated

Kidney score – D2G

1st
pathologist

2nd
pathologist

1st
pathologist

1st
pathologist

2nd
pathologist

1

0

0

0

0

2***

2***

2

0

0

0

0

2***

2***

3

0

0

1

0

1

1

4

0

0

0*

0*

0

0

5

0

0

1*

0*

0

1

6

0

0

0

0*

1**

1

7

0

0

0

0

0

0

8

0

0

0

0

2***

0

9

1

0

0

0

0

0

10

0

0

0

0

0

0

Notes: *Mineralization of renal epithelium lining renal papilla collecting ducts.
**Mineralized deposits randomly scattered within the cortex and in medulla.
***Indicates mineralized deposits in the cortex associated with inflammatory cells.
Kidney scores: 0 = normal; 1 = minimal inflammation; 2 = mild inflammation; 3 = moderate inflammation; 4 = marked inflammation.
Abbreviations: D2G, mice group treated with 15 mg g-1 body weight with free gentamicin; D2N, mice group treated with 15 mg g-1 body weight with core shell nanostructure.
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Histopathologically, the D2G-treated kidney tissues revealed
minimal to mild lymphocytic inflammation associated with
mineralized deposits (Figure 2). In contrast, the untreated
or D2N tissues typically showed unremarkable to rare small
peri-glomerular aggregates of mononuclear cells.

In vivo efficacy
The antibacterial activities of free gentamicin and the core
shell nanostructures were compared in a S. typhimurium
infection model in AJ 646 mice. The gentamicin nanostructures were tested at 2 different dosages, viz. 5 and 15 µg g–1
to evaluate the efficacy in in vivo bacterial clearance (Table 2).
D1N resulted in significant reduction of viable bacteria both
in the liver (0.46 log10) and in the spleen (0.25 log10) compared
to the untreated control. However, D1G yielded significant reductions of viable bacteria in the liver (0.48 log10)
but not in the spleen relative to those recovered from the
controls. In contrast, statistically significant reductions in the
numbers of viable bacteria in the liver (1.03 log10) and spleen
(0.29 log10) were observed for the D2N in comparison to the
D2G and infected control (P  0.05).

Discussion
Aminoglycosides are one of the most commonly used classes
of antimicrobials against Gram-negative bacteria due to their
high efficacy and low costs, but they have the potential to
produce nephrotoxic and ototoxic side effects.19,20 Basically,
aminoglycosides are low protein-binding drugs that can freely
filter in the kidney glomeruli upon parenteral administration
without metabolization in the body. However, around 10% of
an administered aminoglycoside such as gentamicin can selectively accumulate in kidney tissue and may cause structural
and functional damage to the renal tubular cells. Thus,
development of new strategies aiming to prevent their accumulation in the renal tissues is highly desirable for reducing
toxicity. Also, though aminoglycosides are highly efficacious

in vitro, their in vivo activity is limited by an inability to
traverse through the phagocytic cell membrane. This is because
intracellular penetration of a drug molecule depends on its
polarity, and polar drugs cannot permeate readily across nonpolar, lipophilic cell membranes. Hence, aminoglycosides such
as gentamicin which are cationic and polar have relatively low
permeabilities across cell membranes.18
One means to reduce toxicity and improve efficacy is to
favor delivery of drugs to the infected organs. In the case of
systemic infection with S. typhimurium, the target organs of
infection are the spleen and liver.19 By encapsulating drug
molecules in polymeric core-shell nanostructures where
the physico-chemical characteristics of the shell have been
designed to interact with lipid membranes, internalization by
the tissue macrophage cells can be improved. This reduces
transport of free gentamicin to renal tissues and enhances
targeting to the liver or spleen. In this research, we utilized
an amphiphilic Pluronic F-68 copolymer as the shell, and
gentamicin was incorporated into the nanoparticle cores
through cooperative electrostatic attractions. To fabricate
the nanostructured complexes, a polyanionic PAA- +Na
homopolymer 10 and PAA - +Na-b-PEO-b-PPO-b-PEOb-PAA - +Na block copolymer were co-dissolved and a
polycationic gentamicin sulfate solution20 was added with
sonication to form a final one-to-one ratio of anions to cations.
In general, the polyacrylate components formed the core of the
complex while the nonionic blocks extended outward into the
aqueous medium to form the shells, so the polyacrylate homopolymer was used to “build up” the sizes and drug loadings of
the cores as shown schematically in Figure 1. The non-ionic
polyether shell afforded steric repulsion between particles and
prevented macroscale agglomeration. The nanostructures prepared via this technique had a drug loading of ∼25% by weight
of the polymer. However, while the 25% drug loading is high,
it is noteworthy to observe that a significant amount of the
charged drug was not incorporated and better understanding

Table 2 Efficacy cfu (log) reduction of free gentamicin or core-shell nanostructure polymers in liver and spleen from Salmonella-infected
mouse
Treatment

Liver cfu (log) (CI)

Liver cfu (log) reduction

Spleen cfu (log) (CI)

Spleen cfu (log) reduction

Infected control

4.18 (3.98, 4.29)

0.00

3.89 (3.76, 4.28)

0.00

D1N

3.72 (3.28, 3.88)

0.46*

3.64 (3.50, 3.69)

0.25*

D1G

3.70 (3.29, 3.75)

0.48*

3.98 (3.83, 4.01)

-0.09

D2N

3.11 (2.99, 3.53)

1.07*

3.60 (3.48, 4.02)

0.29*

D2G

3.95 (3.92, 3.98)

0.23

4.23 (4.13, 4.32)

-0.34

*Significantly different from control (P  0.05).
Abbreviations: cfu, coloning forming units; CI, confidence interval; D1N, mice group treated with 5 mg g-1 body weight wiht core shell nanostructure; D2N, mice group treated
with 15 mg g-1 body weight with core shell nanostructure; D1G, mice group treated with 5 mg g-1 body weight with free gentamicin; D2G, mice group treated with 15 mg g-1 body
weight with free gentamicin.
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of this issue will be topic for continuing research. Also,
gentamicin releases from the core-shell nanostructure could
be a function of cooperativity between the homo and block
copolymers and drug. This is evidenced from our previous
findings wherein rate of release of gentamicin from nanostructure with pluronic F68 shell was relatively slow compared to
free gentamicin at physiological pH 7.4 and 37°C.14,21 Even
though the overall complexes had a significant net negative
charge, they had small zeta potentials in DI water, ranging
from –0.7 (±0.2) mV. This suggests that the non-ionic PEO
and PEO-b-PPO-b-PEO shells effectively screened the
excess of anionic charges in the core from the environment.22
It has also been suggested that the rate of particle uptake by
macrophage cells increases with an increase in size with the
minimum recognizable size of ∼70 to 85 nm.23,24 In our experimental analysis, we observed that the size of the core-shell
nanostructure was ∼210 (±17) nm but a systematic study of
the effect of size has not yet been conducted.
The core-shell nanostructures can be potentially realized
in clinical situations by ruling out any toxicity associated with
their use in biological systems. This was determined in vitro
via an MTS assay which measures mitochondrial activity
through the formation of a soluble formazan product which
is directly proportional to the number of live cells in culture.25
MTS assays conducted upon incubation of cells with the coreshell nanostructures containing gentamicin showed no significant differences in absorption compared to untreated control,
indicating that the polymers at doses similar to that of the
free gentamicin or untreated control were non-toxic in vitro
(Figure 2). Further, in vivo studies of renal histopathology
were performed independently by two anatomic pathologists

Core-shell nanostructures encapsulating gentamicin

to screen for microscopic lesions. Each kidney was given a
subjective score from 0 (unremarkable) to 4 (marked). Both
evaluators noted minimal to mild increased inflammation
in half of the kidneys in the mice group treated with free
gentamicin. Additionally, both evaluators noticed mineral
deposits within the renal cortex associated with inflammatory cells and these lesions were not present in kidneys from
the untreated or core-shell nanostructure treated groups of
mice. These lesions are consistent with either the deposition
of a mineralized substance eliciting inflammation or chronic
regions of inflammation with dystrophic mineralization. The
inflammatory infiltrate in these kidneys were predominantly
comprised of lymphocytes and macrophages, as has been
similarly observed previously for gentamicin nephrotoxicity.26
However, the kidneys did not exhibit distended tubules,
hyaline casts, tubular degeneration, glomerular basement
membrane alterations or necrosis reported in gentamicin
toxicity.27,28 Plausibly, the single dose administration of gentamicin at 15 µg g–1 body weight of mice may not have been
enough to cause concentration dependent toxicity. Repeated
administration for multiple times/days to the mice similar
to previous studies may shed more light on the protective
effects of gentamicin encapsulation against nephrotoxicty.27
Regardless, unremarkable to minimal renal lesions in
untreated and core-shell nanostructure-treated mice suggest
that gentamicin encapsulation may be protective in preventing
adverse effects in the kidney.
Finally, AJ-646 mice were infected with S. typhimurium
and treated with the core-shell nanostructures. The results
indicated that at a 15 µg g–1 dose, free gentamicin was
ineffective in bacterial clearance. In contrast Salmonella was

Figure 3 Histopathological microscopic images of kidney tissues of AJ-646 mice euthanized 5 days after intraperitoneal administration: A) Untreated control group;
B) D2G-treated group: Minimal to mild lymphocytic inflammation (green arrow) associated with mineralized deposits (orange arrows); C) D2N-treated group: Typically
unremarkable to rare small peri-glomerular aggregates of mononuclear cells (arrow). The tissues were hematoxylin and eosin stained. Scale bar represents 50 µm.
Abbreviations: D2G, mice group treated with 15 mg g-1 body weight with free gentamicin; D2N, mice group treated with 15 mg g-1 body weight with core shell nanostructure.
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reduced significantly in the liver and spleen tissues in the
D2N treated group. Significant reductions in Salmonella were
also observed on administration of multiple doses of D1N at
5 µg g–1 in the spleen and liver and in the liver of D1G-treated
mice respectively. Previous studies conducted with liposomes
in an in vivo Salmonella infection model have suggested that
the gentamicin levels in plasma, liver and spleen are increased
significantly upon encapsulation.29 This consequently has
a favorable effect on the bacterial clearance as evidenced
by 104 reductions in the cfu counts of spleen and liver tissue.
In addition, encapsulation increases the circulation time of
the drug, thereby enhancing delivery to the target organ of
infection and preventing the free drug from reaching the
renal tissues.30 Furthermore, uptake studies in our laboratory
have shown that increased amphiphilicity of the gentamicinpolymer core-shell nanostructure significantly improves the
amount and rate of uptake by the macrophage cells.21 Thus,
improved efficacy in Salmonella clearance by the D2N-treated
mice could be an interplay of both enhanced delivery and
increased uptake by the tissue macrophage cells.
Altogether, the current study shows that improved
efficacy and delivery to the infected organs can be achieved
by incorporating gentamicin in pluronic-based coreshell structures. This has a protective effect in preventing
adverse toxic effects on the kidney. Future studies aiming
to improve the intracellular targeting to the niche where the
Salmonella reside may enhance the suitability of the coreshell antimicrobial DDS systems.
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